Home » Stocks » INSM

Insmed, Inc. (INSM)

Stock Price: $36.24 USD -1.13 (-3.02%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 3.69B
Revenue (ttm) 168.71M
Net Income (ttm) -244.87M
Shares Out 101.62M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $36.24
Previous Close $37.37
Change ($) -1.13
Change (%) -3.02%
Day's Open 37.07
Day's Range 35.54 - 37.75
Day's Volume 675,323
52-Week Range 13.63 - 40.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

BRIDGEWATER, N.J., Dec. 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dis...

Zacks Investment Research - 1 month ago

Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.

PRNewsWire - 1 month ago

BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare di...

PRNewsWire - 2 months ago

BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare di...

PRNewsWire - 2 months ago

BRIDGEWATER, N.J., Nov. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dis...

Seeking Alpha - 2 months ago

Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Insmed (INSM) delivered earnings and revenue surprises of -6.78% and -6.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 2 months ago

BRIDGEWATER, N.J., Oct. 29, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare di...

PRNewsWire - 2 months ago

BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dise...

Zacks Investment Research - 2 months ago

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 months ago

BRIDGEWATER, N.J., Oct. 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare di...

24/7 Wall Street - 3 months ago

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

Other stocks mentioned: ALXN, AMGN, BMRN, REGN, UTHR, VRTX
PRNewsWire - 4 months ago

BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dis...

PRNewsWire - 4 months ago

BRIDGEWATER, N.J., Sept. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dis...

Investors Business Daily - 4 months ago

On Friday, Insmed (INSM) hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 83, up from 79 the day before.

Seeking Alpha - 5 months ago

Insmed Incorporated (INSM) CEO William Lewis on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Insmed (INSM) delivered earnings and revenue surprises of -10.34% and 16.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 5 months ago

BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dise...

Zacks Investment Research - 5 months ago

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 5 months ago

BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dis...

PRNewsWire - 5 months ago

BRIDGEWATER, N.J., July 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare di...

PRNewsWire - 6 months ago

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dise...

PRNewsWire - 6 months ago

BRIDGEWATER, N.J., June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dis...

PRNewsWire - 7 months ago

BRIDGEWATER, N.J., June 8, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare dise...

Seeking Alpha - 8 months ago

Insmed Incorporated (INSM) CEO Will Lewis on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Insmed (INSM) delivered earnings and revenue surprises of -10.45% and 9.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Insmed (NASDAQ:INSM) were unchanged at $21.05 after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Seeking Alpha - 10 months ago

Insmed, Incorporated (INSM) CEO Will Lewis on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 11 months ago

Shares jump in response to a pair of analyst upgrades.

The Motley Fool - 11 months ago

Shares soar after Insmed reports upbeat clinical news.

24/7 Wall Street - 11 months ago

Insmed Inc. (NASDAQ: INSM) is one of the few biotechs not tied to the coronavirus that is making a big move to start out the week.

Investors Business Daily - 11 months ago

Insmed stock rocketed Monday after the biotech company said its non-cystic fibrosis bronchiectasis treatment showed promise in a Phase 2 study. Patients experienced fewer exacerbations.

Market Watch - 11 months ago

Shares of Insmed Inc. INSM, -1.11% rocketed 51% toward a nine-month high in premarket trading Monday, after the biopharmaceutical company said a phase 2 trial of its treatment of non-cystic fi...

InvestorPlace - 11 months ago

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

Other stocks mentioned: ATEC, BDSI, BTAI, FOLD, GERN, INO
Zacks Investment Research - 1 year ago

Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Seeking Alpha - 1 year ago

Insmed, Inc. (INSM) CEO Will Lewis on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

After a solid second quarter, investors in the biopharmaceutical company were left to wonder about management’s tepid growth forecast.

GuruFocus - 1 year ago

Chairman, President & CEO of Insmed Inc (NASDAQ:INSM) William Lewis sold 400,000 shares of INSM on 06/25/2019 at an average price of $26 a share.

Seeking Alpha - 1 year ago

Insmed, Inc. (INSM) CEO William Lewis on Q1 2019 Results - Earnings Call Transcript

About INSM

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a... [Read more...]

Industry
Biotechnology
IPO Date
Jun 1, 2000
CEO
William Lewis
Employees
435
Stock Exchange
NASDAQ
Ticker Symbol
INSM
Full Company Profile

Financial Performance

In 2019, Insmed's revenue was $136.47 million, an increase of 1,287.56% compared to the previous year's $9.84 million. Losses were -$254.34 million, -21.57% less than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Insmed stock is "Strong Buy." The 12-month stock price forecast is 50.80, which is an increase of 40.18% from the latest price.

Price Target
$50.80
(40.18% upside)
Analyst Consensus: Strong Buy